Cd48 Antibody Market was valued at USD 1 billion in 2025 and is projected to reach USD 2 billion by 2035, registering a CAGR of 9.3%. Increasing applications in immunotherapy, targeted cancer treatments, and antibody-based drug development are contributing to market expansion.
Cancer immunotherapy is a major application segment, valued at approximately USD 400 million in 2024 and projected to reach USD 1 billion by 2035. Autoimmune diseases, infectious diseases, transplantation rejection, and research and development also represent important areas for CD48 antibody research and commercialization.
Monoclonal, polyclonal, and recombinant antibodies form the primary product categories. Monoclonal antibodies are particularly relevant because of their target specificity, while recombinant antibody technologies are supporting efforts to improve affinity, specificity, and potential therapeutic performance.
Pharmaceutical companies, academic institutions, contract research organizations, and hospitals and clinics participate across the CD48 antibody value chain. Collaboration between research organizations and biopharmaceutical companies is supporting development of novel antibody-based therapies and clinical applications.
